Cetera Investment Advisers Sells 8,761 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Cetera Investment Advisers trimmed its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 12.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 64,157 shares of the medical research company's stock after selling 8,761 shares during the period. Cetera Investment Advisers' holdings in IQVIA were worth $12,608,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Norges Bank acquired a new stake in IQVIA in the 4th quarter valued at $336,041,000. Raymond James Financial Inc. acquired a new stake in shares of IQVIA during the 4th quarter worth about $236,120,000. American Century Companies Inc. lifted its holdings in IQVIA by 396.0% during the 4th quarter. American Century Companies Inc. now owns 1,134,737 shares of the medical research company's stock valued at $222,987,000 after purchasing an additional 905,960 shares during the last quarter. Invesco Ltd. grew its stake in IQVIA by 53.4% during the fourth quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company's stock worth $509,012,000 after buying an additional 902,226 shares during the last quarter. Finally, Canada Pension Plan Investment Board raised its stake in shares of IQVIA by 20.0% in the fourth quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company's stock valued at $841,461,000 after acquiring an additional 712,958 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have commented on IQV shares. Mizuho reduced their price objective on IQVIA from $242.00 to $210.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 9th. Morgan Stanley raised their price objective on shares of IQVIA from $245.00 to $250.00 and gave the company an "overweight" rating in a research report on Tuesday, February 11th. Barclays reduced their target price on shares of IQVIA from $170.00 to $165.00 and set an "equal weight" rating on the stock in a research report on Wednesday, May 7th. Stifel Nicolaus dropped their price objective on shares of IQVIA from $273.00 to $261.00 and set a "buy" rating for the company in a research report on Friday, February 7th. Finally, Robert W. Baird lowered their target price on IQVIA from $195.00 to $161.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. Eight investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $231.71.

IQVIA Price Performance

Shares of IQV stock traded down $5.39 on Tuesday, hitting $150.74. 2,499,662 shares of the company's stock were exchanged, compared to its average volume of 1,491,694. The stock has a market cap of $26.08 billion, a P/E ratio of 20.10, a price-to-earnings-growth ratio of 1.99 and a beta of 1.34. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 12 month low of $135.97 and a 12 month high of $252.88. The company has a 50 day moving average of $163.31 and a 200 day moving average of $187.68.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, beating analysts' consensus estimates of $2.63 by $0.07. The company had revenue of $3.83 billion during the quarter, compared to analysts' expectations of $3.77 billion. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. IQVIA's revenue was up 2.5% compared to the same quarter last year. During the same period in the prior year, the company earned $2.54 EPS. On average, equities research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.